ESPA's Product Differentiation

Our major innovation is that the products will not only address specific disease, but also risk factors for ailments which often accompany the targeted ailment therefore play an important role in prevention

​

• Targeting the biochemical sites of disease origin and not only symptoms.

• Combining systemic approach and topical management.

• Addressing and managing the increased risk of co-morbidities, such as diabetes, cardiovascular and cardiometabolic diseases and arthritis as well as comorbidities if clinically manifest.

• High efficacy and well-established safety profile supported by preclinical and clinical research. Biochemical targets similar to those targeted by biological treatment.

• Low-cost and easily accessible “OTC” products.